Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Entrada Therapeutics, Inc.

Market Cap 255M 223M 206M 193M 362M 24.11B 364M 2.45B 949M 11.87B 959M 938M 41.2B P/E 2026 *
-1.75x
P/E 2027 * -1.87x
Enterprise Value 162M 141M 131M 122M 230M 15.29B 231M 1.55B 601M 7.52B 608M 595M 26.12B EV / Sales 2026 *
10.8x
EV / Sales 2027 * -2.55x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day+4.11%
1 week+9.75%
Current month+0.28%
1 month+12.36%
3 months-37.31%
6 months-35.43%
Current year-31.03%
1 week 6.35
Extreme 6.35
7.2
1 month 5.76
Extreme 5.76
7.2
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 2017-07-31
Director of Finance/CFO 47 2020-10-31
President 56 2023-12-31
Director TitleAgeSince
Director/Board Member 50 2017-07-31
Chairman 44 2020-11-30
Director/Board Member 67 2020-11-30
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

19,000 0.0489%
06-09Free

Director

19,000 0.0489%
06-09Free

Director

19,000 0.0489%
Change 5-day change 1-year change 3-year change Capi.($)
+4.11%+9.75%-0.42%-53.20% 255M
+1.44%-1.25%+64.25%+116.08% 55.19B
+4.60%+3.02%+57.38%+62.27% 45.75B
-1.44%+0.39%-14.68%-15.42% 22.98B
-2.69%-2.10%-6.70%+363.03% 20.76B
-0.91%-1.10%+24.82%-18.99% 16.26B
+0.58%+1.08%+18.85%-36.52% 15.42B
-1.01%-2.30%+28.59%+173.07% 13.05B
+4.95%+11.70%+125.78%+261.94% 12.45B
-5.92%-6.68%+19.41% - 12.37B
Average +0.38%+3.29%+31.73%+94.70% 21.45B
Weighted average by Cap. +0.81%+1.52%+39.94%+104.26%

Financials

2026 *2027 *
Net sales 14.99M 13.07M 12.1M 11.33M 21.25M 1.41B 21.38M 144M 55.65M 696M 56.27M 55.06M 2.42B 29.81M 25.99M 24.07M 22.53M 42.26M 2.81B 42.52M 286M 111M 1.38B 112M 109M 4.81B
Net income -176M -153M -142M -133M -249M -16.59B -251M -1.68B -653M -8.17B -660M -646M -28.36B -188M -164M -151M -142M -266M -17.7B -268M -1.8B -696M -8.71B -704M -689M -30.25B
Net Debt -93.49M -81.51M -75.49M -70.67M -133M -8.82B -133M -896M -347M -4.34B -351M -343M -15.08B -331M -289M -268M -251M -470M -31.27B -473M -3.18B -1.23B -15.39B -1.24B -1.22B -53.45B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
26-06-18 7.090 $ +4.11% 339,761
26-06-17 6.810 $ +4.77% 201,185
26-06-16 6.500 $ -1.14% 173,987
26-06-15 6.575 $ +1.78% 192,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.090USD
Average target price
18.75USD
Spread / Average Target
+164.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!